| Table 1. BASELINE PATIENT CHARACTERISTICS | | | | |
|---|---|---|---|---|
| **N= 180** | | **Mean ± SD** | **Patients** | **n (%)** |
| **Age (years)** | | 59.4±12.2 | | |
| **Gender** | Women | | 82 | (45.6) |
| | Men | | 98 | (54.4) |
| **Smoking History** | Positive | | 103 | (57.3) |
| | Negative | | 77 | (42.7) |
| **Wood-smoke exposure** | Positive | | 73 | (40.6) |
| | Negative | | 103 | (59.4) |
| **ECOG** | 0 | | 38 | (21.1) |
| | 1 | | 115 | (63.9) |
| | 2 | | 26 | (14.4) |
| | 3 | | 1 | (0.6) |
| **Clinical Stage** | III | | 28 | (15.6) |
| | IV | | 152 | (84.4) |
| **Histology** | Adenocarcinoma | | 152 | (84.4) |
| | Squamous-cell | | 14 | (7.8) |
| | Undifferentiated | | 13 | (7.2) |
| | Large-cell carcinoma | | 1 | (0.6) |
| **Baseline CEA** | | 242.8 ± 685 | | |
| **Treatment** | Platinum-Based CT | | 168 | (93.3) |
| | Tyrosine-kinase inhibitors | | 12 | (6.7) |
| **Tumor Response Evaluation** | Complete/Partial | | 51 | (28.3) |
| | Stable Disease | | 89 | (49.4) |
| | Progressive Disease | | 40 | (22.2) |

**Abbreviations**: SD, standard deviation; CEA, carcinoembryonic antigen; CT,

chemotherapy